Clinical Trial Update: Study to Evaluate the Safety and Tolerability of Andecaliximab as Monotherapy and in Combination With Anti-Cancer Agents in Japanese Participants With Gastric or Gastroesophageal Junction Adenocarcinoma [Phase 1]

View source ↗

Summary

Phase 1 trial evaluating andecaliximab as monotherapy and with anti-cancer agents in Japanese patients with gastric or gastroesophageal junction adenocarcinoma;…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Gastric Adenocarcinoma
• Gastroesophageal Junction Adenocarcinoma

Drugs mentioned

• Andecaliximab

Snippet

Sponsor: Gilead Sciences | Conditions: Gastric Adenocarcinoma | Phase 1 | Status: TERMINATED | Results posted: 2020-12-24